DOI: 10.1055/s-00043364

Pharmaceutical Fronts

LinksClose Window

References


Heavy news: Healthgen Biotechnology Cl., Ltd. has successfully completed the phase I clinical study of its plant derived-recombination human serum albumin injection in the United States [in Chinese].
Accessed April 2, 2020 at:
http://www.phirda.com/artilce_21750.html

Download Bibliographical Data

We do not assume any responsibility for the contents of the web pages of other providers.